Racura Oncology has been given the go-ahead to raise the dose in its HARNESS-1 lung cancer trial after a safety review found no dose-limiting toxicities in the first patients treated.

Racura Oncology (ASX:RAC) has been greenlit by a safety committee to increase to 100mg the dose of its novel RC220 drug for ...

AMAZE-lung shows promising activity with amivantamab, lazertinib and bevacizumab after third-generation EGFR TKI resistance ...

A new study shows that a simple index combining hemoglobin and the albumin-to-alkaline phosphatase ratio can predict survival ...

Long-term exposure to cigarette smoke reshapes distinct populations of lung stem cells, and the reshaped cell state deciding ...

Healthline Editor-in-Chief Robin Hough talks with Gini Harrison, a psychologist and his friend of nearly 30 years, who never ...

HIV appears to strip the immune system of its ability to recognize tumor neoepitopes without altering the tumor’s mutational ...

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer. Theodore Wagener, PhD, founding ...

CHOSA Oncology AB received 94 tumour biopsy samples from Mount Sinai Hospital in New York as part of its ongoing research collaboration to evaluate the ability of Platin-DRP® to identify patients with ...

The Lung Cancer Canada Breathe Forward Award is a new $200,000 national innovation challenge supporting practical and ...

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused ...

Target high-unmet-need niches—post-immunotherapy resistance, rare biomarkers and early-stage disease—while tracking therapy uptake, pricing and market access.Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- ...